In both trials , patients in the control arm received docetaxel/cisplatin ; in the experimental arm , patients with low RAP80 expression received gemcitabine/cisplatin , those with intermediate/high RAP80 expression and low/intermediate BRCA1 expression received docetaxel/cisplatin , and those with intermediate/high RAP80 expression and high BRCA1 expression received docetaxel alone .